A 16-year-old boy with arthritis, rash, and hemoptysis: Beyond “undifferentiated connective tissue disease”?  

Wei Bai1,2,3,4, Rongrong Wang5, Min Shen1,2,3,4,*, Mengtao Li1,2,3,4,*, Xiaofeng Zeng1,2,3,4  

1Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China  
2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, Beijing, China  
3State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Beijing, China  
4Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China  
5McKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, China  

Received December 26, 2021 accepted February 16, 2022  

Type I interferonopathy is a group of autoinflammatory disorders characterized by activation of type I interferon (IFN-I) signaling and upregulated expression of IFN-stimulated genes (ISGs). It can present both “autoinflammation” and “autoimmunity” phenomenon, and therefore has overlap manifestations with rheumatic diseases such as systemic lupus erythematosus (SLE). Since IFN-I exerts its functions via JAK/STAT (Janus kinase/signal transduction and activator of transcription) pathways, JAK inhibitors showed efficacy in the treatment of type I interferonopathy. The study reports a 16-year-old patient who suffered from intermittent anemia, rash, arthritis, and hemoptysis and was diagnosed with type I interferonopathy.  

A 16-year-old boy was admitted in Peking Union Medical College hospital because of fatigue, intermittent cough, and fever for 13 years, and dyspnea on exertion for 3 years. The boy had been suffering from intermittent severe anemia with a minimum hemoglobin 30 g/L associated with dark urine, jaundice of skin and sclera for the past 13 years. The examination of thalassemia and other congenital hemolytic anemia was normal. Meanwhile, he had been suffering from relapsing fever, cough, and sputum, which gradually worsened. He also presented with relapsing arthritis involving metacarpophalangeal joints, facial rash, and fingertip and toe erythema for the last 10 years (Figure 1A,B). At the age of 13, he had fever, cough, and hemoptysis. Since then, he began to feel dyspnea on exertion. Pedigree analysis (Figure 2A) revealed that his mother (II-6) had polyarthritis, and frequently had fingertip and toe erythema since her teenage (Figure 1C,D). His aunt (II-9) had intermittent arthralgia. His grandmother (I-4) had also been suffering from polyarthritis mainly involving proximal interphalangeal joints for years. His elder sister (III-5) occasionally had facial rash, and fingertip and toe erythema (Figure 1E,F).  

The complete blood count was normal with hemoglobin 144 g/L. The complete biochemistry panel and urine analysis were within the normal range. The erythrocyte sedimentation rate (ESR) level was elevated (34 mm/h), as well as C-reactive protein (CRP) (27.43 mg/L) and immunoglobulin G (IgG) (18.75 g/L). Serological testing for autoantibodies showed that ANA was positive (1:80, speckle pattern) with positive anticentromere antibody. He also had low-titer lupus anticoagulant, anti-beta2-glycoprotein I (β2GPI), RF, and anti-CCP antibody. His brain natriuretic peptide (BNP) and cardiac troponin I (cTnI) levels were within the normal range. Peripheral vascular ultrasound found no sign of thrombosis. His brain magnetic resonance imaging (MRI) and X-ray of
both hands were normal. The exams showed severe hypoxemia (percutaneous oxygen saturation [SpO₂] 85% at room air and pO₂ 48 mmHg in arterial blood gas [ABG] analysis). Pulmonary function test revealed severe restrictive ventilation dysfunction with decreased diffusion function (forced expiratory volume in 1 s [FEV1]/forced volume vital capacity [FVC] 90.37%, FVC 40.4%, diffusing capacity of the lung for carbon monoxide [DLCO] 20.3%). Chest high-resolution computed tomography (HRCT) scan showed diffused severe ground glass opacity in both lungs (Figure 1G), which were in accordance with chronic recurrent diffuse alveolar hemorrhage (DAH) and pulmonary hemosiderosis. Severe tricuspid regurgitation and pulmonary hypertension (evaluated pulmonary artery systolic pressure [PASP] 97 mmHg) was detected by echocardiography. The right heart catheter (RHC) examination confirmed the precapillary pulmonary artery hypertension (pulmonary artery pressure [PAP] 108/46 (70) mmHg, pulmonary arterial wedge pressure [PAWP] 13 mmHg).

Regarding multiple organ involvements including arthritis, rash, intermittent anemia, severe pulmonary hypertension, interstitial lung disease (ILD), positive ANA, and other autoantibodies, and elevated inflammatory parameters, he was suspected of having undifferentiated connective tissue disease at first. However, many of his manifestations were inexplicable by connective tissue disease, for example, the disease-onset age of 3 years, the normal levels of complements, the low-titer autoantibodies, and the family history of similar symptoms. Therefore, the whole-exome sequencing by next-generation sequencing was performed. Although the genetic testing for existing autoinflammatory diseases, especially type I interferonopathies, was normal, the blood tests of his family members showed that the expression of ISGs was significantly upregulated in the patient and his mother, compared with his father and health control (Figure 2B–G). Hence, he was finally diagnosed with type I interferonopathy.

The patient was treated with tofacitinib 5 mg twice a day and hydroxychloroquine (HCQ) 200 mg twice a day. At 6-month follow-up, his symptom of dyspnea on exertion was relieved and hypoxemia was improved (SpO₂ 95% at room air and pO₂ 79 mmHg in ABG test). The ESR, CRP, and IgG levels returned to normal. The evaluated PASP by echocardiography was decreased (50 mmHg). There was no significant improvement in chest HRCT and mild improvement in pulmonary function test (FEV1/FVC 94.04%, FVC 47.8%, and DLCO 26.9%). At 1-year follow-up, he was stable with normal ESR, CRP, and IgG levels. The ILD in HRCT scan was improved (Figure 1H).

Type I interferonopathy is a group of rare
genetic autoinflammatory disorders characterized by prominent activation of IFN-I signaling.\[1\] Since IFN-I, including IFN-α and IFN-β, affects not only innate immunity, but also adaptive immunity,\[2\] type I interferonopathy may be characterized by autoinflammation manifestations such as fever, cutaneous rash, or intracranial calcifications, and varying autoimmune features such as positive autoantibodies, systemic involvement of pulmonary or kidney, or even SLE-like manifestations.\[3\] It used to be considered as monogenic lupus or lupus-like syndromes years ago.\[4\] Since our patient, as well as his mother, had prominent upregulated expression of ISGs, which meant abnormal activation of IFN-I signaling, atypical manifestation of systemic involvement, positive autoantibodies, and elevated inflammatory parameters, we considered the diagnosis of type I interferonopathy instead of undifferentiated connective tissue disease.

Until now, there have been many reported kinds of type I interferonopathy including Aicardi-Goutières syndrome, STING (Stimulator of interferon genes) -associated vasculopathy with onset in infancy (SAVI), spondylodysplasia with immune dysregulation (SPENCD),\[5\] and coatomer protein subunit alpha (COPA) syndrome, among others.\[6\] Patients with SAVI usually present with systemic inflammation, cutaneous rash, ILD, and pulmonary hypertension.\[7, 8\] As a recently described disease, COPA syndrome is characterized by activation of IFN-I, recurrent DAH, and/or ILD, associated with arthritis, lupus-like nephropathy, and positive antibodies.\[6, 9\] Since our patient had systemic inflammation, facial rash, intermittent anemia due to recurrent DAH, ILD,
and pulmonary hypertension, SAVI and COPA syndrome were the most likely clinical diagnoses. Unfortunately, we did not find any genetic mutations related to type I interferonopathies including SAVI and COPA syndrome. Nevertheless, given the significantly upregulated ISGs, which were detected in the proband and his mother, they could be diagnosed as type I interferonopathy with a combination of their manifestations.

As IFN-I exerts its functions via JAK/STAT pathways, JAK inhibitors were used in type I interferonopathies including SAVI and COPA syndrome and showed good efficacy.\textsuperscript{[10, 11]} The efficacy of tofacitinib in the patient might due to his upregulated ISGs. Furthermore, JAK inhibitors are also a novel therapy for rheumatic diseases such as SLE\textsuperscript{[12, 13]} because of the overactivity of IFN-I pathway in these diseases.\textsuperscript{[12, 14]}

It is inspiring that the progress of type I interferonopathy may provide more insights into the treatment strategies in other rheumatic diseases.

Acknowledgments

We appreciate all support from the patient and his family.

Conflict of Interest

Xiaofeng Zeng is the Editor-in-Chief of the journal, and Mengtao Li is an Associate Editor-in-Chief. The article was subject to the journal’s standard procedures, with peer review handled independently of these members and their research groups.

Informed Consent

The authors certify that they have obtained all appropriate patient consent documents. In the documents, the patient has given his consent for his images and other clinical information to be published in the journal.

Ethical Statement

We have obtained the patients’ written informed consent form for participation in the study and for publication of their data.

Funding

This work was supported by the Natural Science Foundation of Beijing (Grant No. 7192170); the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS) (Grant No. 2017-I2M-3-001); the National Key Research and Development Program of China (Grant Nos 2016YFC0901500; 2016YFC0901501); and CAMS Innovation Fund for Medical Sciences (CIFMS) (Grand No. 2021-I2M-1-005).

References

\[1\] Yu ZX, Song HM. Toward a Better Understanding of Type I Interferonopathies: A Brief Summary, Update and Beyond. World J Pediatr, 2020;16(1):44–51.

\[2\] Kretschmer S, Lee-Kirsch MA. Type I Interferon-Mediated Autoinflammation and Autoimmunity. Curr Opin Immunol, 2017;49:96–102.

\[3\] Crow YJ, Manel N. Aicardi-Goutieres Syndrome and the Type I Interferonopathies. Nat Rev Immunol, 2015;15(7):429–440.

\[4\] Alperin JM, Ortiz-Fernandez L, Sawalha AH. Monogenic Lupus: A Developing Paradigm of Disease. Front Immunol, 2018;9:2496.

\[5\] Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol, 2018;38(1):129–143.

\[6\] Frémond ML, Nathan N. COPA Syndrome, 5 years After: Where are we? Joint Bone Spine, 2021;88(2):105070.

\[7\] Liu Y, Jesus AA, Marrero B, et al. Activated STING in a Vascular and Pulmonary Syndrome. N Engl J Med, 2014;371(6):507–518.

\[8\] Saldanha RG, Balka KR, Davidson S, et al. A Mutation Outside the Dimerization Domain Causing Atypical STING-Associated Vascularopathy With Onset in Infancy. Front Immunol, 2018;9:1535.

\[9\] Vece TJ, Watkin LB, Nicholas S, et al. Copa Syndrome: A Novel Autosomal Dominant Immune Dysregulatory Disease. J Clin Immunol, 2016;36(4):377–387.

\[10\] Gómez-Arias PJ, Gómez-Garcia F, Hernández-Parada J, et al. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review. Dermatol Ther (Heidelb), 2021;11(3):733–750.

\[11\] Krutzke S, Rietschel C, Hornell G. Baricitinib in Therapy of COPA Syndrome in a 15-year-old Girl. Eur J Rheumatol. 2019;7(Suppl 1):1–4.

\[12\] Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. Lancet, 2018;392(10143):222–231.
[13] You H, Zhang G, Wang Q, et al. Successful Treatment of Arthritis and Rash with Tofacitinib in Systemic Lupus Erythematosus: The Experience from a Single Centre. Ann Rheum Dis, 2019;78(10):1441–1443.

[14] Muskardin TLW, Niewold TB. Type I Interferon in Rheumatic Diseases. Nat Rev Rheumatol, 2018;14(4):214–228.